menu
    • menu
    []

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Vandria

                            Switzerland arrow
                            EPS
                            Not Confirmed

                            Vandria

                            Switzerland arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VNA-318

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Innosuisse

                            Deal Size : $2.9 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Vandria Awarded €3.8M in Innosuisse and Eurostars Grants for CNS and Muscle Disease Drugs

                            Details : Through financing, Vandria will focus on the development of lead CNS mitophagy drug candidate VNA-318, which has the potential to treat cognitive impairment, dementia, Alzheimer’s, and Parkinson’s.

                            Product Name : VNA-318

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 02, 2024

                            Lead Product(s) : VNA-318

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Innosuisse

                            Deal Size : $2.9 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Vandria

                            Switzerland arrow
                            EPS
                            Not Confirmed

                            Vandria

                            Switzerland arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VNA-318

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : ND Capital

                            Deal Size : $20.6 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Vandria Announces $20.6M (CHF18M) Series A Financing Led by ND Capital to Drive CNS Clinical Program and Mitoc...

                            Details : The net proceeds will be used to develop first-in-class small molecule mitophagy inducers, including VNA-318, against a novel target to rejuvenate cells and treat age-related and chronic diseases.

                            Product Name : VNA-318

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 14, 2023

                            Lead Product(s) : VNA-318

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : ND Capital

                            Deal Size : $20.6 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Anokion SA

                            Switzerland arrow
                            EPS
                            Not Confirmed

                            Anokion SA

                            Switzerland arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ANK-700

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Anokion Announces FDA Clearance of IND Application for ANK-700 for the Treatment of Multiple Sclerosis

                            Details : U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for ANK-700, an antigen-specific drug candidate for the treatment of multiple sclerosis (MS).

                            Product Name : ANK-700

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 24, 2020

                            Lead Product(s) : ANK-700

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth